Press Releases

Date	Title
July 28, 2020	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 28, 2020	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin
July 23, 2020	Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer
June 30, 2020	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
June 15, 2020	Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting
May 14, 2020	Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting
May 4, 2020	Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update
April 27, 2020	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 1, 2020	Corcept Therapeutics Publishes Abstract in the Journal of the Endocrine Society
March 12, 2020	Corcept Therapeutics Appoints Gregg Alton to Board of Directors